Money Makers Mentor

Kymera Therapeutics Announces $102 Million Series C Financing

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. This funding is to further the advancement of its protein degrader pipeline and platform. In lament terms, they aim to naturally destroy disease causing proteins in the body.

The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Other existing investors also participated in the round.

Kymera also received a strategic investment from The Leukemia…

Leave A Reply

Your email address will not be published.